Skip to main content
SpringerLink
Log in

Entwicklungen neuer Therapiemöglichkeiten des Schlaganfalls

Perspektiven für Neuroprotektiva?

Development of new stroke therapies

Outlook for neuroprotective drugs

  • Aktuelles
  • Published:
Der Nervenarzt Aims and scope Submit manuscript

Zusammenfassung

Schlaganfälle gehören zu den häufigsten Erkrankungen dieser Zeit. Die zahlreichen negativen klinischen Studien mit neuroprotektiven Substanzen führten zur Einführung von Empfehlungen der Stroke Therapy Academic Industry Roundtable (STAIR) für die präklinische und klinische Entwicklungsphase. Als Folge dieser verbesserten neuen Entwicklungen zeigte die erstmalig positive klinische Studie mit dem Radikalfänger NXY-059 ein ermutigendes Ergebnis (SAINT I), das sich allerdings in einer Folgestudie (SAINT II) nicht bestätigen ließ. In diesem Artikel analysieren wir kritisch die präklinische und klinische Entwicklung von Neuroprotektiva für die Schlaganfallbehandlung am Beispiel von NXY-059 und geben Empfehlungen für die mögliche zukünftige Entwicklung neuroprotektiver Substanzen.

Summary

Stroke remains one of the most urgent medical problems of our times. The failure of most neuroprotective drugs in clinical trials led to the initiation of the Stroke Therapy Academic Industry Roundtable guidelines. Due to this improvement, the positive clinical trial results with the free radical scavenger NXY-059 (SAINT I) was encouraging. However, the subsequent SAINT II trial did not confirm these results. In this article we critically review the history of preclinical and clinical trials based on experience of NXY-059 development and present recommendations for potential future preclinical and clinical development of neuroprotective stroke therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Stroke Therapy Academic Industry Roundtable (STAIR) (1999) Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 30: 2752–2758

    Google Scholar 

  2. Bath PM, Sprigg N (2007) Colony stimulating factors (including erythropoietin, granulocyte colony stimulating factor and analogues) for stroke. Cochrane Database Syst Rev: CD005207

    Google Scholar 

  3. Ehrenreich H, Hasselblatt M, Dembowski C et al. (2002) Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 8: 495–505

    PubMed  CAS  Google Scholar 

  4. Fisher M, Hanley DF, Howard G et al. (2007) Recommendations from the STAIR V meeting on acute stroke trials, technology and outcomes. Stroke 38: 245–248

    Article  PubMed  Google Scholar 

  5. Fisher M, Schabitz WR (2000) An overview of acute stroke therapy: past, present, and future. Arch Intern Med 160: 3196–3206

    Article  PubMed  CAS  Google Scholar 

  6. Hacke W, Albers G, Al Rawi Y et al. (2005) The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 36: 66–73

    Article  PubMed  CAS  Google Scholar 

  7. Hacke W, Kaste M, Fieschi C et al. (1995) Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 274: 1017–1025

    Article  PubMed  CAS  Google Scholar 

  8. Schroeder N (2007) Topline-Ergebnisse der DIAS-2-Studie zeigen keinen Unterschied zwischen Desmoteplase und Plazebo. Online Pressemitteilung vom 31.05.2007 http://www.paion.de

  9. Kohrmann M, Juttler E, Fiebach JB et al. (2006) MRI versus CT-based thrombolysis treatment within and beyond the 3 h time window after stroke onset: a cohort study. Lancet Neurol 5: 661–667

    Article  PubMed  Google Scholar 

  10. Kuroda S, Tsuchidate R, Smith ML et al. (1999) Neuroprotective effects of a novel nitrone, NXY-059, after transient focal cerebral ischemia in the rat. J Cereb Blood Flow Metab 19: 778–787

    Article  PubMed  CAS  Google Scholar 

  11. Lapchak PA, Araujo DM, Song D et al. (2002) Neuroprotective effects of the spin trap agent disodium-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) in a rabbit small clot embolic stroke model: combination studies with the thrombolytic tissue plasminogen activator. Stroke 33: 1411–1415

    Article  PubMed  CAS  Google Scholar 

  12. Lees KR, Davalos A, Davis SM et al. (2006) Additional outcomes and subgroup analyses of NXY-059 for acute ischemic stroke in the SAINT I trial. Stroke 37: 2970–2978

    Article  PubMed  Google Scholar 

  13. Lees KR, Zivin JA, Ashwood T et al. (2006) NXY-059 for acute ischemic stroke. N Engl J Med 354: 588–600

    Article  PubMed  CAS  Google Scholar 

  14. Marshall JW, Cummings RM, Bowes LJ et al. (2003) Functional and histological evidence for the protective effect of NXY-059 in a primate model of stroke when given 4 hours after occlusion. Stroke 34: 2228–2233

    Article  PubMed  CAS  Google Scholar 

  15. Marshall JW, Duffin KJ, Green AR, Ridley RM (2001) NXY-059, a free radical–trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species. Stroke 32: 190–198

    PubMed  CAS  Google Scholar 

  16. Ren JM, Finklestein SP (2005) Growth factor treatment of stroke. Curr Drug Targets CNS Neurol Disord 4: 121–125

    Article  PubMed  CAS  Google Scholar 

  17. Rogalewski A, Schneider A, Ringelstein EB, Schabitz WR (2006) Toward a multimodal neuroprotective treatment of stroke. Stroke 37: 1129–1136

    Article  PubMed  Google Scholar 

  18. Rothwell PM, Coull AJ, Silver LE et al. (2005) Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet 366: 1773–1783

    Article  PubMed  CAS  Google Scholar 

  19. Saver JL (2007) Clinical impact of NXY-059 demonstrated in the SAINT I trial: derivation of number needed to treat for benefit over entire range of functional disability. Stroke 38: 1515–1518

    Article  PubMed  Google Scholar 

  20. Savitz SI (2007) A critical appraisal of the NXY-059 neuroprotection studies for acute stroke: a need for more rigorous testing of neuroprotective agents in animal models of stroke. Exp Neurol 205: 20–25

    Article  PubMed  CAS  Google Scholar 

  21. Schabitz WR, Fisher M (2006) Perspectives on neuroprotective stroke therapy. Biochem Soc Trans 34: 1271–1276

    Article  PubMed  Google Scholar 

  22. Schabitz WR, Kollmar R, Schwaninger M et al. (2003) Neuroprotective effect of granulocyte colony-stimulating factor after focal cerebral ischemia. Stroke 34: 745–751

    Article  PubMed  Google Scholar 

  23. Schabitz WR, Schneider A (2007) New targets for established proteins: exploring G-CSF for the treatment of stroke. Trends Pharmacol Sci 28: 157–161

    Article  PubMed  Google Scholar 

  24. Schneider A, Kruger C, Steigleder T et al. (2005) The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J Clin Invest 115: 2083–2098

    Article  PubMed  CAS  Google Scholar 

  25. Schneider A, Kuhn HG, Schabitz WR (2005) A role for G-CSF (granulocyte-colony stimulating factor) in the central nervous system. Cell Cycle 4: 1753–1757

    PubMed  CAS  Google Scholar 

  26. Shuaib A, Lees KR, Lyden P et al. (2007) NXY-059 for the treatment of acute ischemic stroke. N Engl J Med 357: 562–571

    Article  PubMed  CAS  Google Scholar 

  27. Sydserff SG, Borelli AR, Green AR, Cross AJ (2002) Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies on dose, plasma concentration and therapeutic time window. Br J Pharmacol 135: 103–112

    Article  PubMed  CAS  Google Scholar 

  28. Wahlgren NG, Ahmed N (2004) Neuroprotection in cerebral ischaemia: facts and fancies–the need for new approaches. Cerebrovasc Dis [Suppl 1] 17: 153–166

    Google Scholar 

  29. Yoshimoto T, Kanakaraj P, Ying MJ et al. (2002) NXY-059 maintains Akt activation and inhibits release of cytochrome C after focal cerebral ischemia. Brain Res 947: 191–198

    Article  PubMed  CAS  Google Scholar 

  30. Yoshimoto T, Kristian T, Hu B et al. (2002) Effect of NXY-059 on secondary mitochondrial dysfunction after transient focal ischemia; comparison with cyclosporin A. Brain Res 932: 99–109

    PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor weist auf folgende Beziehung/en hin: W.-R. Schäbitz ist Miterfinder einer patentierten Applikation bezüglich der neuroprotektiven Effekte von G-CSF.

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Neurologie, Universitätsklinikum, Albert-Schweitzer-Straße 33, 48129, Münster, Deutschland

    A. Rogalewski & W.-R. Schäbitz

Authors
  1. A. Rogalewski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W.-R. Schäbitz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Rogalewski.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rogalewski, A., Schäbitz, WR. Entwicklungen neuer Therapiemöglichkeiten des Schlaganfalls. Nervenarzt 79, 218–224 (2008). https://doi.org/10.1007/s00115-007-2386-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00115-007-2386-x

Schlüsselwörter

Keywords

Search

Navigation